California Assembly Bill AB1152

California 2025-2026 Regular Session

• Introduced: 2/20/25
• Refer: 3/28/25
• Report Pass: 3/28/25
• Refer: 4/1/25
• Report Pass: 4/28/25
• Refer: 4/28/25
• Report Pass: 5/1/25
• Engrossed: 5/8/25
• Refer: 5/8/25
• Refer: 5/21/25
• Report Pass: 6/23/25
• Refer: 6/23/25
• Refer: 6/24/25
• Refer: 6/25/25
• Report Pass: 7/15/25
• Refer: 7/15/25
• Refer: 9/11/25
• Enrolled: 9/13/25
• Chaptered: 10/1/25
• Passed: 10/1/25

Caption

Controlled substances: human chorionic gonadotropin.

Impact

Should AB 1152 be enacted, it would substantially affect state laws regarding the regulation of controlled substances. By reclassifying hCG, not only would prescriptions for it be easier to obtain, but it would also likely lead to a broader acceptance and use in clinical settings. The legislation reflects a shift toward a more liberal approach to the regulation of medically beneficial substances that are currently hindered by strict controlled substance laws. This could potentially facilitate more research and applications in therapeutic areas that utilize hCG, resulting in improved patient care.

Summary

Assembly Bill No. 1152, introduced by Patterson, proposes to amend the California Uniform Controlled Substances Act by removing human chorionic gonadotropin (hCG) from the list of controlled substances classified under Schedule III. This amendment is significant because it alters the current regulatory framework that governs the prescription, possession, and use of substances deemed to have potential for abuse. Currently, hCG is categorized with controlled substances that have accepted medical uses but also have potential for misuse. The bill aims to facilitate easier access to this hormone, particularly in medical contexts where it is used for treatments such as infertility and weight management.

Sentiment

The sentiment surrounding AB 1152 appears to be predominantly supportive among those in the medical community who advocate for the need to expand treatment options for patients. Proponents argue that the restrictions on hCG do not align with its medical uses, emphasizing that its removal from Schedule III would more accurately reflect its accepted use in medical practice. However, there are also concerns raised by various stakeholders regarding the implications of loosening regulations on a substance that could theoretically be misused, particularly in contexts of weight loss and performance enhancement.

Contention

Notable points of contention include the risk of hCG being misused beyond its intended medical applications, particularly in the realms of sports and weight-loss practices. Critics argue that easing restrictions could lead to hCG being used inappropriately for performance enhancement in athletics or unregulated weight loss programs. While the bill aims to address legitimate medical needs, it raises questions about the regulatory implications and the need for safeguards to prevent abuse, indicating a need for a balanced approach between patient access and prevention of misuse.